Immune Checkpoint PD-1/PD-L1: Is There Life Beyond Antibodies?

Area of Science:

• Immunology
• Oncology
• Structural Biology

Background:

• The PD-1/PD-L1 pathway is a critical regulator of the immune response and a validated target in cancer immunotherapy.
• Monoclonal antibodies targeting PD-1/PD-L1 have demonstrated significant clinical efficacy across multiple tumor types.

Purpose of the Study:

• To highlight the significance of the PD-1/PD-L1 interaction as a therapeutic target in cancer.
• To emphasize the role of structural information in the development of novel cancer inhibitors.

Main Methods:

• Review of existing literature on PD-1/PD-L1 interaction and cancer immunotherapy.
• Analysis of cocrystal structures of human PD-1 and PD-L1.
• Consideration of recent crystal structures involving inhibitors (monoclonal antibodies, small molecules, macrocycles).

Main Results:

• The PD-1/PD-L1 interaction is a crucial target for cancer immunotherapy.
• Structural data, including cocrystal structures, are instrumental for rational drug design.
• Existing therapies like monoclonal antibodies show promise.

Conclusions:

• The cocrystal structure of human PD-1 and PD-L1 provides a foundation for designing novel inhibitors.
• Integrating structural insights from antibodies, small molecules, and macrocycles will accelerate the development of next-generation cancer immunotherapies.